CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

glatiramer acetate (Copaxone, Glatopa) for relapsing multiple sclerosis

Covers use of FDA‑approved glatiramer acetate formulations for treatment of relapsing forms of multiple sclerosis in adults when approval criteria are met; applies to members of Neighborhood Health Plan of Rhode Island without exclusions to the therapy.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

Policyglatiramer acetate (Copaxone, Glatopa) for relapsing multiple sclerosis

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document diagnosis and neurologist prescriber/consultation for 12‑month approvals.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthstypical authorization duration

FDA‑approved onlycoverage scope

Neurologyprescriber specialty

Coverage Criteria

Initial and continuation therapy

Covered when ALL of the following are met

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage criteria for glatiramer acetate: 1) Patient has a diagnosis of a relapsing form of multiple sclerosis (includes clinically isolated syndrome, relapsing‑remitting disease, or active secondary progressive disease) in an adult. 2) Medication is prescribed by, or in consultation with, a neurologist. 3) For initiation or continuation, documentation shows disease stability or improvement when applicable. 4) The member is not using glatiramer acetate concomitantly with other disease‑modifying multiple sclerosis agents (Ampyra and Nuedexta are not disease‑modifying and are exceptions).

Authorizations may be granted for 12 months.

Provider Actions and Requirements

Prior Authorization

Prior Authorization — 12‑Month Approvals

Prior authorization is required. Approvals are granted for up to 12 months for both initial and continuation therapy when clinical criteria are met.

Authorization duration: 12 months for initial and continuation therapy
Indications covered: relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing‑remitting, and active secondary progressive disease)

Documentation Required

Required Documentation

Documentation supporting the medical necessity of therapy must be provided with the prior authorization request.

Diagnosis documentation confirming a relapsing form of MS (including clinically isolated syndrome, relapsing‑remitting, or active secondary progressive disease)
Clinical notes demonstrating disease activity or rationale for therapy initiation or continuation
For continuation requests, documentation of disease stability or improvement while on therapy

Denial Risk

Concomitant Therapy Restrictions

Concomitant use of glatiramer acetate products with other disease‑modifying multiple sclerosis (DMT) agents is not permitted. Ensure the member is not receiving more than one DMT concurrently.

Prohibited concomitant therapy: Copaxone, Glatopa, or generic glatiramer acetate used at the same time as any other disease‑modifying MS agent
Note: Ampyra and Nuedexta are not disease‑modifying therapies and are not included in this restriction

Background

Glatiramer acetate (Copaxone, Glatopa, generic glatiramer acetate) is indicated for the treatment of adults with relapsing forms of multiple sclerosis, which includes clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease. Treatment is limited to these FDA‑approved populations; use outside these indications is considered experimental/investigational and not medically necessary.

Definitions

Relapsing forms of multiple sclerosis

DefinitionRelapsing forms of multiple sclerosis include clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease in adults per FDA‑approved indication.

Age populationAdults (per FDA labeling).

ScopeApplies to FDA‑approved relapsing forms of MS only; other indications are considered experimental/investigational and not medically necessary.

Relevant productsGlatiramer acetate formulations (e.g., Copaxone, Glatopa, generic glatiramer acetate) when used for relapsing forms of MS.